Experimental Study About The Effects Of Gubenfangxiaoyin On IL-6,13 Expression Of Balf In Rats With Chronic Bronchial Asthma

Currently bronchial asthma is the most common chronic respiratory disease, whose incidence has been increasing with the development of society. Asthma has become a grave public health problem drawing worldwide attention. In Clinical, Chinese medicine treatment of chronic asthma has unique advantages. The prescription Gubenfangxiao decoction (GBFXD) is an empirical prescription from Professor Jiang Yuren who is a countrywide famous pediatrician. It provided the effects of nourishing lung, secured exterior, invigorated spleen and resolved phlegm. GBFXD is an effective prescription to cure childhood asthenia of pulmonosplenic qi. GBFXD is clinical safety. Currently in the national science pillar program, named as "The effects of Gubenfangxiaoyin on the susceptibility gene (ADAM33 and ORMDL3) of asthma and related regulatory、signal transduction", has reached the experimental stage. The experimental research part of our work belongs to this project, it investigates further mechanism of GBFXD as well as its active components preventing and curing asthma using views of cytokines mainly.ObjectExplore the mechanism of GBFXD polysaccharides preventing and curing asthma remission period using views of observing the levels of IL-6 and IL-13 in mouse bronchoalveolar lavage fluid (BALF).MethodsBALB/c mice were sensitized with intraperitoneal OVA injection and atomization inhalation, and then the asthma model was reproduced in the Balb/C mice challenged by repeated inhalation of ovalbumin(OVA) and repeated intranasal instillation of RSV. The model mice which stopped inspire were divided into six groups:normal control group, asthma model group, montelukast sodium group, high dose GBFXD group, medium dose GBFXD group, low dose GBFXD group. The IL-6 and IL-13 levels in BALF was observed 24 hours after last administration. Data analysis was done with SPSS 13.0.ResultsThe IL-6 level in the remission of asthma model group mice significantly increased compared with normal group, the difference was statistically significant (P<0.01),The IL-6 levels in the montelukast sodium group, high dose GBFXD group, medium dose GBFXD group, low dose GBFXD group decreased significantly than the model group (P<0.01). The effect of GBFXD group was much better than montelukast sodium group (P<0.01)The IL-13 level in the remission of asthma model group mice significantly increased compared with normal group, the difference was statistically significant (P<0.01), The IL-13 levels in the montelukast sodium group, medium dose GBFXD group, low dose GBFXD group decreased significantly than the model group (P<0.01). The curative effect of the high dose GBFXD group and the montelukast sodium group was different obviously (P<0.01)ConclusionThe GBFXD can reduce the levels of IL-6 and IL-13 in BALF. This research indicates that the GBFXD is significant in the treatment of asthma in remission.